April 18 (Reuters) - Neovacs SA ALNEV.PA :
* FUNDRAISING OF 0.5 MEUR
* SET UP A FINANCING IN THE FORM OF OCEANE-BSA WITH THE
EUROPEAN
HIGH GROWTH OPPORTUNITIES SECURITIZATION FUND, WHICH, AFTER
RECEIVING THE SHARES RESULTING FROM THE CONVERSION OR EXERCISE
OF THESE INSTRUMENTS, WILL NOT REMAIN A SHAREHOLDER OF THE
COMPANY
* THE SHARES RESULTING FROM THE CONVERSION OR EXERCISE OF
THE
ABOVE-MENTIONED SECURITIES WILL, IN GENERAL, BE SOLD IN THE
MARKET AT VERY SHORT NOTICE, WHICH MAY CREATE STRONG DOWNWARD
PRESSURE ON THE SHARE PRICE
* THE NET PROCEEDS OF THIS OPERATION (€480,000) WILL BE USED
TO
FINANCE THE KINOÏDE® ALLERGY RESEARCH PROGRAM 2 (50%) AND TO
STRENGTHEN THE COMPANY'S CAPACITY TO INVEST IN PROMISING
PROJECTS, BOTH IN THE DEVELOPMENT OF DRUG CANDIDATES (BIOTECH)
AND MEDICAL DEVICES (MEDTECH)
Source text for Eikon: ID:nACT79400
Further company coverage: ALNEV.PA
(Gdansk Newsroom)
((Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))